Introduction {#s1}
============

A major problem confronting large-scale genomic sequencing studies of disease patients is to identify those genetic variants that actually represent disease-causing mutations. This is particularly true for candidate genes that have not previously been evaluated in an experimental model system for involvement in disease-relevant biological processes. Functional gene validation systems in model organisms are therefore essential. While a definitive assignment of disease association should be established through the analysis of mutant gene phenotypes in a mammalian model, this approach is not practical for rapid high-throughput initial screening of large numbers of candidate genes. *Drosophila*, by contrast, possesses the attributes of a simple animal model system that make it ideally suited for this role ([@bib3]; [@bib7]).

Use of *Drosophila* as a model to elucidate molecular disease mechanisms is well established and amply documented ([@bib5]; [@bib22]; [@bib34]; [@bib9]; [@bib2]; [@bib27]). It has been established that 75% of human disease associated genes are represented in the fly genome by functional homologs ([@bib28]). Although it is difficult to directly link *Drosophila* developmental defects to patient symptoms, the *Drosophila* system can serve as a testing platform for gene function in development, which can be used to test disease association for a large number of candidate genes identified from patient genomic sequencing.

Congenital heart disease (CHD) affects 0.8% of live births ([@bib16], [@bib15]; [@bib29]). Genetic factors are strongly implicated in CHD pathogenesis, but the great majority of genes (accounting for an estimated 75% of cases) remain unidentified ([@bib11]). *Drosophila* has served as a model to study genes related to CHD for over 20 years, based on the evolutionarily conserved genetic basis of heart development ([@bib2]; [@bib26]; [@bib32]). The *Drosophila* heart ([Figure 1A](#fig1){ref-type="fig"}) is a rhythmically beating linear tube composed of parallel rows of fused contractile cardiac cells, flanked by adherent pericardial cells ([@bib30]). The heart functions to maintain circulation of hemolymph (insect 'blood') throughout the body cavity. In a typical beating cycle, hemolymph enters the posteriorly-located heart chamber in the abdomen and is pumped anteriorly through the aorta towards the head and brain. Although structurally of relatively low complexity, *Drosophila* and human heart development are both largely directed by the same highly conserved regulatory networks ([@bib30]). To demonstrate that the fly is the ideal in vivo animal model for cost-effective, rapidly informative, and efficient screening of candidate disease genes, we have developed a *Drosophila* validation system to screen candidate genes identified in a large-scale genomic sequencing study of congenital heart disease patients.10.7554/eLife.22617.003Figure 1.*Drosophila* adult heart structure and tissue visualization, evaluation of 1X vs. 4X *Hand* enhancer constructs driving heart specific silencing of gene expression.(**A**) *Drosophila* heart structure and visualization. **Left:** the adult heart is depicted schematically in green. Supporting lateral alary muscles are depicted in red. **Middle:** fluorescence microscopy of dissected heart tissue spanning abdominal segments A2--A5. Myocardial actin filaments (cardiac myofibers) were visualized by Phalloidin staining (red), which also stained somatic muscle fibers in segments A2, A3, and A4 and alary muscle fibers in A5. GFP (green) labels cardiomyocytes and pericardial nephrocytes. Expression of a nuclear-localized GFP transgene was controlled by the cardioblast specific *Hand* gene enhancer element. Scale bar = 100 µ. **Right:** higher magnification of segment A4 heart tissue. Scale bar = 50 µ. In this example, dissection and preparation for microscopy involved removal of a layer of longitudinal muscle, which resulted in the loss of some cardiomyocytes and pericardial nephrocytes. In situ, the heart tube is composed of parallel, symmetrical rows of cardiomyocytes (small nuclei), flanked by pericardial nephrocytes (large nuclei). (**B**) The 4XHand enhancer promotes significantly greater Gal4 mRNA production than the single Hand enhancer. The Gal4 mRNA level in the dissected adult heart was determined by qRT-PCR. Statistical significance (\*) was defined as p\<0.05. *w^1118^* was used as a negative control since it does not express any Gal4. (**C**) Compared to the single Hand enhancer, 4XHand induced significantly greater knockdown of CG8184 (the homolog of human *HUWE1*) mRNA when driving expression of the CG8184-IR RNAi silencing transgene. The CG8184 mRNA level in the dissected adult heart was determined by qRT-PCR. Statistical significance (\*) was defined as p\<0.05. (**D**) Compared to the single Hand enhancer, 4XHand induced significantly greater knockdown of Lid (the homolog of human *KDM5A* and *KDM5B*) mRNA when driving expression of the Lid-IR RNAi silencing transgene. The Lid mRNA level in the dissected adult heart was determined by qRT-PCR. Statistical significance (\*) was defined as p\<0.05. In **C** and **D**, Control flies were the progeny of a cross between homozygous 4XHand-Gal4 and *w^1118^*, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.003](10.7554/eLife.22617.003)10.7554/eLife.22617.004Figure 1---figure supplement 1.4XHand-Gal4 efficiently silences cardiac gene expression.(**A**) Mortality Index, expressed as the percentage of flies of the indicated genotype that die during pre-adult stages. Male and female flies of the appropriate genotypes were crossed to produce progeny flies carrying the indicated UAS-gene silencing (i.e. RNAi) interfering RNA (IR) construct, the expression of which is directed specifically in cardioblast cells by the indicated Hand-Gal4 driver. Hand-Gal4 and 4X-Hand-Gal4 constructs incorporate either one copy or four tandem copies of a Hand gene enhancer element, respectively. Significant developmental lethal effects of heart-specific gene silencing were only observed in progeny flies carrying the 4XHand-Gal4 driver.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.004](10.7554/eLife.22617.004)

In 2013 the Pediatric Cardiac Genomics Consortium (PCGC) published a large-scale sequence analysis of sporadically occurring CHD cases ([@bib33]), providing an opportunity to conduct systematic model system based experimental studies into the genetic basis of CHD, informed from the outset by clinical data. Such studies will ultimately facilitate the development of diagnostic, therapeutic, and preventive approaches, and precision medicine interventions ([@bib1]) for CHD. The initial report ([@bib33]) of 249 protein-altering de novo mutations from 362 severe cases of CHD identified 223 candidate disease genes involved in diverse biochemical pathways, with 26 genes selected as particular genes-of-interest based upon bioinformatics criteria ([@bib33]). We used *Drosophila* developmental genetics to quantitatively evaluate the phenotypes associated with heart-specific RNAi mediated gene silencing of fly homologs of mutated candidate disease genes. 174 genes (78%) had clear fly homologs, consistent with the published estimate of 75% conservation of disease gene homologs ([@bib28]). Interestingly, the 'top 26' genes identified by the PCGC study ([@bib33]) all have conserved *Drosophila* homologs. Some of these genes were previously identified as having roles in *Drosophila* heart development, in the context of a global in vivo RNAi screen for candidate fly heart genes. ([@bib23]) The current study used a stronger heart-specific driver to validate candidate CHD genes.

We developed a highly efficient cardiac-targeted gene silencing approach in flies, and used this to examine effects on heart structure and function for fly homologs of 134 candidate disease genes published by the PCGC. We employed a quantitative phenotypic screening protocol that evaluated developmental lethality (pre-adult mortality), heart structure ([Figure 1A](#fig1){ref-type="fig"}; including morphology, cardiac myofibrillar density, cardiac collagen deposition, and cardioblast cell number) and adult longevity. We found that 52% of the tested fly homologs are required for cardiac development and function in flies. We also developed a gene replacement testing strategy involving simultaneous heart-specific silencing of an endogenous fly gene homolog and expression of either wild type or patient-derived mutant alleles of the candidate human disease gene.

Results {#s2}
=======

To achieve a highly efficient heart-specific gene knock down, we generated a strong cardiac cell Gal4 driver featuring 4 tandem repeats of the *Drosophila Hand* gene cardiac enhancer ([@bib12]). We compared the levels of Gal4 RNA in heart tissues of transgenic flies carrying the new 4XHand-Gal4 driver construct versus flies carrying the original, established Hand-Gal4 driver (featuring a single *Hand* enhancer element). As anticipated, 4XHand promoted significantly higher heart cell expression of Gal4 mRNA ([Figure 1B](#fig1){ref-type="fig"}). We then compared the Hand-Gal4 and 4XHand-Gal4 drivers together with UAS-Gene-IR RNAi based silencing constructs ([@bib24], [@bib25]) for gene knock down efficiency when used to silence expression (i.e. lower heart cell RNA levels) of *Drosophila* genes *CG8184* ([Figure 1C](#fig1){ref-type="fig"}) and *Lid* ([Figure 1D](#fig1){ref-type="fig"}). Consistent with the higher Gal4 expression, 4XHand was significantly more effective at silencing target gene expression through RNAi. To further confirm the utility of 4XHand-Gal4 for screening purposes, we comparatively evaluated the Hand-Gal4 and 4XHand-Gal4 constructs driving heart-specific expression of UAS-RNAi transgenes targeting eight *Drosophila* genes for developmental lethal (death at pre-adult stage) effects. The *Hand* enhancer is active during development from embryonic stages, and we reasoned that *Hand* enhancer-driven silencing of genes known to be essential for heart development would cause developmental lethality. For this assay, male and female flies of the appropriate genotypes were crossed to produce progeny carrying the indicated UAS-gene silencing (i.e. RNAi) interfering RNA (IR) construct, the expression of which was driven by Hand-Gal4 or 4XHand-Gal4. Progeny embryos were collected and allowed to develop under standard conditions. The results were quantitatively expressed as a Mortality Index (MI), the percentage of flies that died before adult emergence from the pupa stage. We found that for all eight tested genes, significant developmental lethal effects of heart-specific gene silencing were only observed in flies carrying a 4XHand-Gal4 driver ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

We combined the new 4XHand-Gal4 driver with available fly lines carrying UAS-Gene-IR RNAi based silencing constructs to evaluate for heart specific essential function (i.e. MI) the homologs of all genes from the PCGC study for which multiple independent UAS-RNAi lines are available (134 total genes, [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). We extracted the data for the PCGC top 26 genes, identified as most-promising candidate disease genes on the basis of multiple bioinformatics-based criteria ([Figure 2A](#fig2){ref-type="fig"}). We reasoned that if these criteria alone were truly informative, the majority of these genes would yield higher MI scores, overall, than observed among all 134 tested genes representing the PCGC total list. As shown in [Figure 2](#fig2){ref-type="fig"} we observed MI values ranging across a spectrum spanning Normal (≤6%, equivalent to nonbiased control genes), Low (7--30%), Medium (31--60%), to High (61--100%). Importantly, we found that the distribution of MI values across all ranges was not significantly different for the top 26 genes compared to the entire cohort of 134 candidate genes tested ([Figure 2A](#fig2){ref-type="fig"}). Thus, selection of candidate CHD genes on the basis of bioinformatics criteria alone did not enrich for genes inducing more severe developmental mortality phenotypes (indicative of more genes with essential roles in either heart development, tissue maintenance, or function). This observation emphasizes the importance of screening and selecting most-promising candidate genes on the basis of functional assays. To determine if the set of 134 candidate genes in itself can be demonstrated to be enriched for heart-essential genes, we examined previously obtained data from a screen of approximately 800 *Drosophila* genes silenced using the 4XHand-Gal4; UAS-RNAi system. These genes were randomly chosen to screen for effects on pericardial nephrocyte function (cardioblast lineage cells in which the *Hand* enhancer is active), so they are unbiased with respect to essential heart roles. We found that only 6% of these genes showed *any level* of developmental lethality when silenced (i.e. 94% normal). Thus, the PCGC genomic association study, though not gene selection based upon bioinformatics criteria, did enrich significantly for heart-essential genes as assayed in *Drosophila*. That such a small number of unbiased genes conferred a phenotype of silencing-induced developmental lethality also suggests that overexpression of 4xHand-Gal4 itself did not sensitize flies to RNAi mediated knockdown effects.10.7554/eLife.22617.005Figure 2.Top 26 candidate CHD genes and developmental lethality induced by heart specific RNAi-based silencing of *Drosophila* gene homologs.(**A**) 26 de novo mutated genes from CHD study participants selected as being of particular interest ([@bib33]) based upon sequence quality, mutation type, the expression level of the mouse homolog during heart development on embryonic day 14.5, and previously reported involvement in CHD or heart development. The 26 corresponding *Drosophila* homologs are shown with protein function (Flybase), and Mortality Rate (Mortality Index). (**B**--**D**) The proportions of *Drosophila* gene homologs that, when silenced by cardiac cell specific RNAi expression, induce developmental lethality at normal/background levels (blue); low levels (green); medium levels (orange); high levels (red) based on Mortality Index values. The Mortality Index is determined by crossing homozygous UAS-RNAi transgenic flies with flies bearing a 4XHand-Gal4 'driver' (four repeats of the cardioblast cell-specific *Hand* enhancer element 5' of *Gal4*) balanced over *CyO*. Progeny flies that emerge as adults with curly wings (*CyO*, no transgene expression) vs. straight wings (expressing 4XHand-Gal4 driven UAS-RNAi transgene in cardioblasts) are recorded and the developmental mortality attributable to RNAi heart expression (Mortality Index) is calculated as (Curly -- Straight) / Curly X 100. Divergence from 1:1 ratio (Normal, blue) ≥ 7% was considered a lethal phenotype. A Normal range of divergence from a 1:1 ratio of \<6% based on analysis of 400 progeny from control crosses. Varying degrees of phenotype severity were observed (Low = 7--30%, green; Medium = 31--60%, orange; High = 61--100%, red). (**B**) Left: chart (PCGC top 26) shows proportions of RNAi silencing effects on lethality for *Drosophila* homologs of 26 genes identified as being of particular interest based exclusively on bioinformatics-based criteria. Right: chart (PCGC total list) shows the results of 134 fly homologs of all de novo mutated genes (with available RNAi silencing lines) identified in pediatric CHD study participants ([@bib33]) ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). (**C**) Comparison of silencing-induced lethality for *Drosophila* homologs of 134 candidate CHD-associated genes as a function of high (HHE) *versus* low (LHE) levels of expression of murine homologs in embryonic mouse heart. (**D**) Comparison of silencing-induced lethality for *Drosophila* homologs of 134 candidate CHD-associated genes as a function of fly-to-human gene conservation (High Conservation, score 6 to 10; Low Conservation, score 2 to 5).**DOI:** [http://dx.doi.org/10.7554/eLife.22617.005](10.7554/eLife.22617.005)

We also stratified and compared MI values we obtained for all of the 134 *Drosophila* genes as functions of expression level of murine homologs during mouse embryonic heart development, as reported in the PCGC study (and one basis for selection of top 26 genes) ([@bib33]). As shown in [Figure 2C](#fig2){ref-type="fig"}, high heart expression (HHE) during development did not correlate with greater severity of developmental lethality associated with gene silencing in *Drosophila* heart. Contrary to expectation, low heart expression (LHE) of murine homologs was associated with relatively higher severity of *Drosophila* gene silencing. These observations again emphasize the importance of applying functional screening assays to the results of genomic sequencing studies. We noted nevertheless that the top 26 genes all have *Drosophila* homologs, including 22 that are highly conserved. When mortality was assayed as a function of degree of fly-human conservation among all 134 tested genes ([Figure 2D](#fig2){ref-type="fig"}) we did observe greater mortality among highly conserved genes compared to less conserved genes. Not surprisingly, phylogenetic conservation indeed correlated positively with MI, a result that further supports using *Drosophila* as a model for functional evaluation of candidate genes for disease association.

In order to confirm that RNAi based phenotypes were indeed associated with target gene mRNA reduction, we measured RNA levels in heart tissue from flies expressing silencing constructs targeting six different genes from the top 26 group. These genes were chosen for analysis because they represent a range of different cellular functions, and include three genes for which silencing did not induce developmental lethality. MI values for the six genes ranged from normal to 43%. As shown in [Figure 3](#fig3){ref-type="fig"}, heart RNA levels of target genes were all significantly reduced. Furthermore, we tested developmental lethal phenotypes for all top 26 genes using two or more independent RNAi silencing fly lines for each gene, and obtained consistent MI results in all cases (data not shown).10.7554/eLife.22617.006Figure 3.Target gene mRNA levels in adult fly heart tissues.(**A**) *Drosophila Cul3* homolog of human *CUL3* encoding ubiquitin ligase (Mortality Index 43%). (**B**) *Drosophila Scny* homolog of human *USP44* encoding ubiquitin protease (Mortality Index 25%). (**C**) *Drosophila Bre1*homolog of human *RNF20* encoding ubiquitin ligase E3 (Mortality Index 13%). (**D**) *Drosophila Rab10* homolog of human *RAB10* encoding GTPase (Mortality Index normal). (**E**) *Drosophila Med20* homolog of human *MED20* (Mortality Index normal). (**F**) *Drosophila CG15445* homolog of human *NUB1* (Mortality Index normal). mRNA levels in dissected adult hearts were determined by qRT-PCR. Statistical significance (\*) was defined as p\<0.05. Control flies were the progeny of a cross between homozygous 4XHand-Gal4 and *w^1118^*, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.006](10.7554/eLife.22617.006)

Eight of the top 26 gene homologs encode products involved in histone H3K4 and H3K27 methylation ([Figures 2A](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Epigenetic activating (H3K4me) and inactivating (H3K27me) marks are associated with selective activation of promoters and enhancers, and chromatin marks are associated with specification and differentiation of cardiac cells ([@bib31]), murine heart development ([@bib14]; [@bib8]), and cardiac pathogenesis ([@bib18]; [@bib35]). Two additional top 26 genes (SUV420H1 and HUWE1) also encode conserved histone modifying proteins. Thus 42% of the top candidate genes from the PCGC study are involved in histone modification pathways, and all but one are highly conserved. Because chromatin modification pathway associated genes represent the major functional class among the 'top 26', we chose to examine in more detail the roles of these genes in *Drosophila* heart morphogenesis and function.10.7554/eLife.22617.007Figure 4.Genes involved in H3K4 and H3K27 methylation, mutated in CHD patients, affect heart structure, developmental mortality, and adult survival.(**A**) Depiction of nucleosome showing H3K4 and H3K27 methylation, and ubiquitination of H2BK120 (required for H3K4 methylation). *Drosophila* homologs involved in the production, removal, or interpretation of modifications are shown (human genes shown in red). (**B**) Adult heart phenotype induced by cardioblast-specific expression (driven by 4XHand-Gal4) of UAS-RNAi transgenes targeting *Kismet* and *Trx*. Cardiac actin (myofibers) was visualized by Phalloidin staining. Hand-GFP expression (nuclear) labels cardioblast cells. Pericardin was immune-labeled. Dotted lines delineate the heart tube outline. Red arrow points to remnant cardioblast cell in Trx-silenced heart. Scale bar = 50 µ. (**C**) Quantitation of adult heart cardiac myofibrillar density (as % of control; N = 10 for Control, N = 6 for indicated silenced gene). Statistical significance (\*) was defined as p\<0.05. Scale bar = 50 µ. (**D**) Quantitation of adult heart cardiac collagen (Pericardin) deposition (as % of control; N = 10 for Control, N = 6 indicated silenced gene). Statistical significance (\*) was defined as p\<0.05. (**E**) Quantitation of adult heart cardioblast cell numbers (cardioblasts expressing nuclear GFP; N = 10 for Control, N = 10 for indicated silenced gene). Statistical significance (\*) was defined as p\<0.05. (**F**) Percentage of adult male flies dead at day 25 post-emergence (N = 50 flies per genotype). (**G**) Larva (third instar) heart phenotypes induced by cardioblast-specific expression (driven by 4XHand-Gal4) of UAS-RNAi transgenes targeting *Wds*, *Kismet*, and *Trx*. Cardiac actin (myofibers) was visualized by Phalloidin staining. The pericardin was immune-labeled. Dotted lines delineate heart tube outline. (**H**) Quantitation of larval heart cardiac myofibrillar density (as % of control; N = 10 for Control, N = 6 for indicated silenced gene). Statistical significance (\*) was defined as p\<0.05. (**I**) Quantitation of larva heart cardiac collagen (Pericardin) deposition (as % of control; N = 10 for Control, N = 6 for indicated silenced gene) Statistical significance (\*) was defined as p\<0.05. Control flies were the progeny of a cross between homozygous 4XHand-Gal4 and *w^1118^*, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.007](10.7554/eLife.22617.007)10.7554/eLife.22617.008Figure 4---figure supplement 1.Genes involved in H3K4 and H3K27 methylation, mutated in CHD patients.(**A**) Adult heart phenotype induced by 4XHand-Gal4 driven expression of UAS-RNAi transgenes targeting UbcD6 and Lid. Left to right panels: cardiac myofibers visualized by Phalloidin staining, cardioblast cells labeled by Hand-GFP expression (nuclear), Pericardin (Type IV collagen) immuno-labeled, merged images. Scale bar = 50 µ. (**B**) Adult fly survival curves (N = 50 flies per genotype). Control flies were homozygous for w1118 and carried the 4XHand-Gal4 transgene, but not a UAS-RNAi silencing construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.008](10.7554/eLife.22617.008)

We analyzed heart phenotypes resulting from cardiac-specific silencing of the eight genes involved in H3K4 and H3K27 methylation ([Figure 4](#fig4){ref-type="fig"}). Silencing *kismet* yielded an adult heart phenotype in which the heart tube was severely affected ([Figure 4B](#fig4){ref-type="fig"}) with very low cardiac myofibrillar density ([Figure 4C](#fig4){ref-type="fig"}), elevated Pericardin (collagen) deposition ([Figure 4D](#fig4){ref-type="fig"}), and reduced numbers of cardioblasts ([Figure 4E](#fig4){ref-type="fig"}). Adult fly longevity was significantly affected, with approximately 50% of flies dead by day 25 ([Figure 4F](#fig4){ref-type="fig"}). During development, *kismet* silencing caused 54% mortality ([Figure 2A](#fig2){ref-type="fig"}). In larvae, cardiac myofibrillar density was reduced with pronounced heart tube filament disruption ([Figure 4G,H](#fig4){ref-type="fig"}), and Pericardin over-expression with disorganized ECM deposition ([Figure 4G,I](#fig4){ref-type="fig"}). *Trx*-silenced adult flies lacked cardiac actin and heart tube ([Figure 4B,C](#fig4){ref-type="fig"}), exhibited severely reduced Pericardin ([Figure 4D](#fig4){ref-type="fig"}), almost no cardioblast cells ([Figure 4E](#fig4){ref-type="fig"}), and all were dead at day 25 after emergence, compared to 20% mortality among control flies ([Figure 4F](#fig4){ref-type="fig"}). *Trx* silencing caused 35% developmental lethality ([Figure 2A](#fig2){ref-type="fig"}). In larvae, knock down of *trx* induced abnormal heart tube structure ([Figure 4G](#fig4){ref-type="fig"}) with reduced cardiac myofibrillar density ([Figure 4G,H](#fig4){ref-type="fig"}) and reduced Pericardin ([Figure 4G,I](#fig4){ref-type="fig"}). Silencing of *wds* caused complete developmental lethality ([Figure 2A](#fig2){ref-type="fig"}) and a dramatic larva heart phenotype ([Figure 4G](#fig4){ref-type="fig"}) featuring abnormal cardiac actin organization and fiber density ([Figure 4H](#fig4){ref-type="fig"}), and extremely high levels of Pericardin ([Figure 4G,I](#fig4){ref-type="fig"}). Taken together, these results strongly suggest that H3K4 methylation is critical for normal heart development and function, a conclusion supported by the observation that knockdown of the H3K4 de-methylase Lid had no phenotypic consequences ([Figure 4C--F,H,I](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Similarly, silencing of SMOX (involved in H3K27 de-methylation) resulted in minimal developmental mortality (MI 7%, [Figure 2A](#fig2){ref-type="fig"}) but normal cardiac myofibrillar density and Pericardin levels in larvae ([Figure 4H,I](#fig4){ref-type="fig"}). The adult heart phenotype was essentially normal, as was adult mortality at day 25 ([Figure 4](#fig4){ref-type="fig"}).

Ubiquitination of H2BK120 ([Figure 4A](#fig4){ref-type="fig"}) is required for H3K4 methylation, and we observed that silencing of the *UbcD6* gene resulted in 84% developmental mortality ([Figure 2A](#fig2){ref-type="fig"}) and reduced adult longevity ([Figure 4F](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The adult heart was severely affected ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) with greatly reduced cardiac myofibrillar density ([Figure 4C](#fig4){ref-type="fig"}), elevated Pericardin ([Figure 4D](#fig4){ref-type="fig"}), and reduced cardioblast cell numbers ([Figure 4E](#fig4){ref-type="fig"}). Silencing of Bre1 and Scny also caused developmental mortality and cardiac myofibrillar density was somewhat reduced in larvae and adults ([Figure 4C,H](#fig4){ref-type="fig"}). Pericardin levels, cardioblast cell numbers, and adult mortality at day 25 were essentially normal ([Figure 4D,E,F,I](#fig4){ref-type="fig"}). By contrast, H3K4 de-methylation did not appear critical as evidenced by the essentially normal heart phenotype, normal MI, and normal adult longevity observed upon *Lid* silencing. ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These results further demonstrate the utility of the *Drosophila* system to functionally test large-scale clinical genomics data and gain insights into fundamental pathways contributing to disease pathogenesis.

We used dye angiography to measure effects on heart function of cardiac-specific silencing of the eight genes involved in H3K4 and H3K27 methylation ([Figure 5](#fig5){ref-type="fig"}). Briefly, fluorescent dye was injected into the posterior abdomen of pharate (pre-eclosion) adult flies, where it entered the heart chamber and was pumped anteriorly. Dye accumulation in the head over a 30 s time interval provided a measurement of cardiac efficiency ([Figure 5A,B](#fig5){ref-type="fig"}) ([@bib10]). We observed that in normal control flies fluorescent dye is readily detectable in the head within 15 s of injection, and significantly accumulated by 30 s. By contrast, silencing of candidate CHD gene homologs involved in the methylation of H3K4 and H3K27 profoundly impaired cardiac function ([Figure 5B,C](#fig5){ref-type="fig"}). Silencing of *Smox* and *Lid*, however, did not measurably impair heart function as measured in this assay. These observations indicate that H3K4 and H3K27 methylation, and not demethylation, is essential for heart function, consistent with our findings with regard to cardiac tissue morphology and effects on developmental lethality and adult longevity.10.7554/eLife.22617.009Figure 5.Direct measurement of heart function.(**A**) The adult heart is depicted schematically in green. Supporting lateral alary muscles are depicted in red. Fluorescent dye injected into the posterior body cavity (arrow) enters the heart tube lumen and is pumped anteriorly into the brain region. (**B**) Time course of injected fluorescent dye entering the brain region (dotted outline). In normal control flies dye is easily detectable 15 s (s) after injection, and the brain is highly fluorescent within 30 s. In flies expressing heart-specific *Wds* or *Kismet* gene targeting RNAi silencing constructs, by contrast, dye does not reach the brain by 30 s after injection. Scale bar = 100 µ. (**C**) Quantitative analysis of brain region fluorescence, relative to control fly levels, as a function of heart-specific gene silencing. Experiments were performed in triplicate (3 independent dye injection experiments). Statistical significance (\*) was defined as p\<0.05. Control flies were the progeny of a cross between homozygous 4XHand-Gal4 and *w^1118^*, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.009](10.7554/eLife.22617.009)

Gene silencing using available and well-established UAS-RNAi fly lines allows rapid and efficient functional screening of large numbers of candidate genes. We also established an in vivo platform to analyze the cardiac phenotypes of specific patient-derived alleles of candidate CHD genes in *Drosophila*, employing a 'gene replacement' strategy. As a proof-of-concept, we tested the ability of a wild type human WDR5 allele to rescue heart phenotypes induced by silencing of the endogenous *wds Drosophila* homolog. Heart-specific silencing of *wds* caused 100% developmental lethality and abnormal heart morphology in late larvae characterized by reduced cardiac myofibers and severe over-deposition of Pericardin ([Figure 6](#fig6){ref-type="fig"}). We found that simultaneously overexpressing a wild type human WDR5 allele reduced developmental lethality almost 7-fold, significantly restored cardiac myofibrillar density, and reduced Pericardin levels essentially to normal ([Figure 6](#fig6){ref-type="fig"}). By contrast, when the endogenous *wds* expression was 'replaced' by a CHD patient-derived WDR5-K7Q mutant allele, developmental lethality remained quite elevated, cardiac myofibrillar density remained abnormally low (relative both to Control and wild type WDR5 rescue), and Pericardin levels were lowered but still significantly higher than both Control and wild type WDR5 rescue. These observations illustrate the structure-function homologies between human and fly 'heart genes' that support use of *Drosophila* for functional validation of candidate CHD genes. Moreover, they demonstrate that the 'gene replacement' strategy can be used to quantitatively assess phenotypes induced by patient-specific alleles of candidate disease genes.10.7554/eLife.22617.010Figure 6.*Wds* silencing-induced lethality and heart phenotypes rescued by wild type human *WDR5* but not by a patient derived *WDR5-K7Q* mutant allele.(**A**) Developmental lethality (Mortality Index) for flies in which endogenous *Wds* heart expression was silenced, and attempted rescue by either wild type *WDR5* or mutant *WDR5-K7Q* overexpression (OE). (**B**) Larva (third instar) heart phenotype induced by cardioblast-specific expression (driven by 4XHand-Gal4) of UAS-RNAi transgene targeting *Wds*, and attempted rescue by *WDR5* or *WDR5-K7Q* overexpression. Cardiac actin (myofibers) visualized by Phalloidin staining. Pericardin was immune-labeled. Dotted lines delineate the heart tube outline. (**C**) Quantitation of larval heart cardiac myofibrillar density (as % of control; N = 10 for Control, N = 6 for Wds-IR, Wds-IR+WDR5-OE, or Wds-IR+WDR5-K7Q-OE). Statistical significance (\*) was defined as p\<0.05. For each strain, fiber density was significantly lower than control. Rescue by wild type WDR5 significantly rescued fiber density, to levels significantly greater than achieved by the overexpression of the WDR5-K7Q mutant allele. (**D**) Quantitation of larva heart cardiac collagen (Pericardin) deposition (as % of control; N = 10 for Control, N = 6 for Wds-IR, Wds-IR+WDR5-OE, or Wds-IR+WDR5-K7Q-OE) Statistical significance (\*) was defined as p\<0.05. Wild type WDR5-OE fully rescued up-regulated collagen deposition induced by Wds-IR. Mutant WDR5-K7Q-OE partially rescued the Wds-IR phenotype, but collagen deposition levels remained upregulated compared to the control. The control flies were the progeny of a cross between homozygous 4XHand-Gal4 and *w^1118^*, which has one copy of 4xHand-Gal4 but does not carry a UAS-RNAi silencing construct.**DOI:** [http://dx.doi.org/10.7554/eLife.22617.010](10.7554/eLife.22617.010)

Discussion {#s3}
==========

Our results demonstrate the value of the *Drosophila* model system to functionally screen and validate candidate disease genes identified through large scale sequencing efforts. The high-throughput testing platform described here can extend gene association data to quantitative, in vivo morphological and functional criteria. On the basis of this screening, the most promising genes can justifiably be advanced to more costly, time consuming, and technically challenging validation platforms required to definitively identify and confirm disease-causing gene variants. Such advanced testing, we presume, will encompass gene function analysis in a mammalian model system.

The advantages of functional screening using RNAi-based silencing lines are to some extent offset by certain limitations. From the outset, of human disease genes, approximately 25% are not represented by *Drosophila* homologs. False negatives may occur if RNAi expression does not sufficiently reduce mRNA levels. However, we tested a number of RNAi lines by qRT-PCR and found no examples of ineffective gene silencing. False negatives may also occur when missense mutations produce gain-of-function (GOF) alleles, and we cannot accurately predict the degree to which this could confound our analysis. This problem, we note, is mitigated to a degree by the fact that genes altered by GOF mutations would in many instances *normally* encode proteins with cardiac cell functions, and thus yield silencing induced phenotypes in our functional screening system. False positives can arise from so-called 'off target' effects of a given RNAi targeting construct. We controlled against misleading results from both RNAi silencing inefficiency and off target effects by employing the latest-generation available RNAi lines, and testing multiple such lines for each of the top 26 candidate genes. This precaution against false negative and false positive results further limited the total number of candidate genes we could screen to 134 (60% of the CHD candidate genes published by the PCGC). Nevertheless, our in vivo screening system rapidly and efficiently confirmed roles in heart development, tissue maintenance, or cardiac function for 72 candidate genes.

Phenotypic analysis based on gene silencing, while effective for high throughput screening, represents a first step in validation and characterization of candidate mutations. We also demonstrated an initial 'gene replacement' strategy that takes further advantage of the available resources and sophisticated genetics of the *Drosophila* model system to quantitatively characterize the phenotype induced by expression of a specific patient-derived mutant allele. This approach may prove highly valuable as a testing platform for precision medicine based therapeutic drugs. Ultimately, the knowledge that a specific mutation contributes to disease pathogenesis opens the door to the application of precise gene-editing interventions, strategies for which are currently being developed based on CRISPR/Cas-9 mediated genome editing ([@bib20]; [@bib6]; [@bib21]). The high throughput candidate gene validation studies reported here represent the essential first step in the functional confirmation, phenotypic characterization, and ultimate precision treatment of disease-associated mutations.

Materials and methods {#s4}
=====================

Fly stocks {#s4-1}
----------

*Drosophila* lines were obtained from the Bloomington Stock Center (Bloomington, IN; NIH P40OD018537). Transgenes were overexpressed with the *UAS-GAL4* system ([@bib4]). To increase the penetrance of heart-specific UAS-RNAi mediated gene silencing we developed a powerful Gal4 driver incorporating four repeats of the *Hand* gene ([@bib13]) enhancer. 4XHand-Gal4 was generated by tandem insertions of the original Hand cardiac-specific enhancer ([@bib12]) in the pGal4 vector.

DNA cloning and generation of transgenic fly strains {#s4-2}
----------------------------------------------------

The wild type *WDR5* cDNA was obtained from OriGene, which encodes the 334 a.a. protein with GenBank ID P61964. The *WDR5-K7Q* cDNA was generated by introducing the K7Q mutation into the wild type *WDR5* cDNA sequence using PCR. To generate *UAS-WDR5* and *UAS-WDR5-K7Q* constructs, the above cDNAs were cloned into the *pUASTattB* vector and the transgenes were introduced into a fixed chromosomal docking site by germ line transformation.

Dye angiography {#s4-3}
---------------

Pharate (pre-eclosion) adult flies were carefully removed from pupa cases and affixed by double-sided scotch tape to glass slides. A single injection of 100 nl of uranin solution (1 µg/µl in PBS) was delivered into the abdomen using a Drummond Nanoject II auto-nanoliter injector with a glass capillary. Dye accumulation in the fly head was monitored over a 3 min interval using a Zeiss ApoTome.2 microscope with a 5x Plan-Neofluar 0.16 air objective. Experiments were performed in triplicate (3 independent dye injection experiments). ImageJ software Version 1.49 was used for image processing and quantification. Fluorescence intensity in the fly head was measured at times 0 (time of injection) and 30 s post-injection. Increased fluorescence values represent fluorescence at t = 30 s minus t = 0, and were expressed relative to head fluorescence of control flies not expressing an RNAi targeting transgene.

qRT-PCR analysis {#s4-4}
----------------

RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA) from heart tissue dissected from 60 adult flies of the relevant genotype. RNA purity and concentration were determined using a Nanodrop-1000 (Thermo Scientific, Wilmington, DE). Total RNA (1 μg) was reverse transcribed using Superscript IV (Invitrogen). SYBR Green based real-time qPCR (Power Cyber Mastermix; Applied Biosystems, Carlsbad, CA) was performed using a StepOne Plus (Applied Biosystems). Gene-specific primer pairs were used. Quantitative values were determined using the 2^-ΔΔCT^ method ([@bib19]), normalizing to Gapdh. Values are derived from three technical replicates of qRT-PCR experiments from pooled RNA.

Fly imaging {#s4-5}
-----------

Fly preparation and imaging are described in more detail at Bio-protocol ([@bib36]). Larvae and adult flies were dissected and fixed for 10 min in 4% paraformaldehyde in phosphate-buffered saline (PBS). Alexa Fluor 555 Phalloidin was obtained from Thermo Fisher. Mouse anti-Pericardin antibody (EC11) was used at 1:500 dilutions, followed by Cy3-conjugated secondary antibodies (Jackson Lab). Confocal imaging was performed with a Zeiss ApoTome.2 microscope using a 20× Plan-Apochromat 0.8 N.A. air objective. For quantitative comparisons of intensities, common settings were chosen to avoid oversaturation. ImageJ Software Version 1.49 was used for image processing. For quantitative comparisons of cardiac myofibrillar density, cardioblast cell numbers, and Pericardin deposition we analyzed six to ten control flies and six to ten flies of each experimental genotype. These features were quantitatively assessed in the same area of the same segment in each fly. Cardiac myofiber levels of Z-stack projections were carefully selected for analysis, avoiding the ventral muscle layer underlying the heart tube. Sample size determinations were based upon extensive previous experience in analyzing fly heart morphology.

Survival assay {#s4-6}
--------------

Within 24 hr of egg laying *Drosophila* larvae were transferred from 25°C to 29°C to boost UAS-transgene expression. Adult male flies were maintained at 29°C in groups of 15 or fewer; 50 flies in total were assayed per genotype.

Statistical analysis {#s4-7}
--------------------

Statistical tests were performed using PAST.exe software (<http://folk.uio.no/ohammer/past/index.html>) unless otherwise noted. Sample errors are given as standard error of the mean (s.e.m). Data were first tested for normality by using the Shapiro-Wilk test (α = 0.05). Normally distributed data were analyzed either by Student\'s *t*-test (two groups) and Bonferroni comparison to adjust p value or by a one-way analysis of variance followed by a Tukey-Kramer post-test for comparing multiple groups. Non-normal distributed data were analyzed by either a Mann-Whitney test (two groups) and Bonferroni comparison to adjust the p value or a Kruskal-Wallis H-test followed by a Dunn\'s test for comparisons between multiple groups. Statistical significance was defined as p\<0.05.
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10.7554/eLife.22617.011

###### 134 de novo mutated genes from CHD study participants with corresponding *Drosophila* homologs showing conservation score ([@bib17]), function (from Flybase) and mortality index (determined by crossing homozygous UAS-RNAi transgenic flies with flies bearing a 4XHand-Gal4 driver balanced over *CyO*, progeny flies that emerge as adults with curly wings (*CyO*, no transgene expression) vs. straight wings (4XHand-Gal4 driven UAS-RNAi transgene expression in cardioblasts) are recorded and the lethal rate attributable to RNAi heart expression is calculated as (Curly -- Straight / Curly) X 100 = % Mortality).

Patient identification number, human gene, mutation type and category (DH, *d*amaging mutation in gene with homolog expression *h*igh in embryonic day 14.5 mouse heart (emh); CH, mutation in phylogenetically *c*onserved region of gene with homolog expression *h*igh in emh; NH, mutation in phylogenetically *n*onconserved region of gene with homolog expression *h*igh in emh; DL, *d*amaging mutation in gene with homolog expression *l*ow in emh; CL, mutation in phylogenetically *c*onserved region of gene with homolog expression *l*ow in emh; NL, mutation in phylogenetically *n*onconserved region of gene with homolog expression *l*ow in emh) are from ([@bib33]).

**DOI:** [http://dx.doi.org/10.7554/eLife.22617.011](10.7554/eLife.22617.011)

10.7554/eLife.22617.012

###### *Drosophila* lines used to silence expression of genes.

Flies were obtained from either the Bloomington *Drosophila* Stock Center (BDSC) or the Vienna *Drosophila* Resource Center (VDRC). Individual fly lines are identified by source ID numbers. Both the human genes and their corresponding *Drosophila* homologs are listed. Each line carries an inhibitory RNA transgene designed to silence the indicated *Drosophila* gene, cloned downstream of a UAS DNA element. The RNAi transgene is only expressed in cells producing the yeast Gal4 transcription factor.

**DOI:** [http://dx.doi.org/10.7554/eLife.22617.012](10.7554/eLife.22617.012)

10.7554/eLife.22617.013

###### Gene specific PCR primers.

**DOI:** [http://dx.doi.org/10.7554/eLife.22617.013](10.7554/eLife.22617.013)

10.7554/eLife.22617.014
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"High throughput in vivo functional validation of candidate congenital heart disease genes in *Drosophila*\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by K VijayRaghavan as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a significant paper which demonstrates the effectiveness of using *Drosophila* as a rapid screening tool for assessing the possible functional significance of genes identified in genomic screens, e.g. screens for de novo variants associated with congenital heart disease as in Zaidi et al. 2013. Genome-wide RNAi screens have been used previously to identify pathways important for cardiovascular development and cardiac disease in humans (e.g. Kim et al., 2010; Neely et al., 2010; van der Harst et al. 2016), so the approach itself is not particularly novel. In the design used here two RNAis for candidate CHD genes are used to knock down the *Dros* homologues of disease genes in Hand-positive cardioblasts using for the first time a multimerized (4x) Hand enhancer driving Gal4, a design that likely leads to high efficiency knockdown compared to previous approaches. A number of cardiac-related phenotypes were scored, including mortality, adult longevity, muscle fibre density, cardioblast numbers, collagen deposition, and heart tube function. The authors perform screens of the top 26 genes identified by Zaidi et al. including the genes involved in chromatin modification, as well as the larger set of candidate genes for which there were *Dros* homologues. They found a high degree of mortality associated with both sets. Interestingly, knockdown of the top 26 did not lead to more severe mortality than the larger set, potentially highlighting the limitations of bioinformatics alone in identifying the most significant players in human disease and the need to combine with functional analysis. Knockdown of a number of chromatin modifying genes were characterised in more detail. The authors conclude from these results that histone methylation but not demethylation, is essential for heart development in flies. Rescue of the *Dros* knockdown of WDR5 with the human WT gene but not the same gene carrying the candidate disease variant was also presented in a proof-of-principal study.

The work is timely and elegant. Clearly knocking down of genes in fly development as a surrogate for testing the relevance of single amino acid variants present in patients with human disease has its limitations and some of these are discussed, but this is clearly a powerful system for focusing attention on variants with significant affects in this assay for follow up functional studies in mammalian cells or animal models.

A number of issues were identified by the reviewers and those requiring attention are listed below:

Essential revisions:

1\) Could over-expression of 4xHand-Gal4 sensitize flies to RNAi knockdown phenotypes? How would this be tested?

2\) We disagree that gain of function variants will be rare. New insights into this for transcription factors has come to light -- see for example Luna-Zurita et al. Cell 2016 and Bouveret et al. *eLife* 2015 -- even apparently null proteins can have gain of function effects. There are in fact a number of ways through which interruption of conserved domains in multidomain proteins may have gain of function effects. I think this should be considered more carefully in the Discussion in the context of limitations of the approach.

3\) One issue that should be addressed is the rationale for the choice of genes for the various analyses. [Figure 3](#fig3){ref-type="fig"} tests the expression levels of six genes when knocked down, but the choice of these genes, and why all 26 were not tested, is not clear. In fact there are certain biases in this study in the sense that one might expect severe defects in any cell type expressing loss or gain of function alleles for chromatin modifying genes, given their global function in epigenetic regulation. We accept that these examples serve to highlight the phenotyping pathway used and the range of defects that can be generated. However, the paper would be strengthened by including some examples of candidates for the Zaidi study where there is mortality or a strong heart phenotype when the gene is knocked down that reveals its totally unknown functions in heart development and cellular function.

4\) Overall, the description of Methods is seriously lacking in detail. The authors should indicate all of the primer sequences that were used, and all of the RNAi lines should be listed in order that the results can be replicated accurately. The dye angiography method does not include detail about how the data was analyzed.

5\) We are not convinced that appropriate statistical tests were used when comparing multiple genotypes. Our understanding is that simple t-tests might not be appropriate, but analysis of variance should initially be used. Moreover, simple t-tests can only be used when the sample variances are comparable. An expert statistical review is advised.

6\) It is mentioned that \"Interestingly, the \"top 26\" genes identified by the PCGC study all have conserved *Drosophila* homologs, but the involvement of these genes in *Drosophila* heart development had not previously been assessed.\" This is inaccurate. Neely et al. (2010) investigated 18/26 of these genes, many of which when silenced using a similar cardiac-specific approach, reduced lifespan. While all were screened for developmental lethality, only one was categorized as a \"developmentally lethal gene\". The low hit number was potentially due to inadequate RNAi-mediated knockdown relative to that afforded by the 4X-Hand driver described here. Nonetheless, involvement of \~70% of the 26 genes in cardiac development was indeed assessed, and the fact that this highly-related manuscript was not cited and the overlap clarified needs correction.

7\) For all analysis depicted in [Figures 4](#fig4){ref-type="fig"}--[6](#fig6){ref-type="fig"}, information related to the control line(s) or the RNAi stock numbers used, is not provided. This is critical for data interpretation and to rule out genetic background effects, which can contribute to differences in structure/physiology. If the experiments are inappropriately controlled, they must be repeated accordingly. For example, 1118 is not an ideal control for the experiments outlined in [Figure 3](#fig3){ref-type="fig"}.

8\) Unlike developmental/survival analysis following cardiac-restricted RNAi expression, structural assessments, and fluorescent dye pumping capacity, which have all been performed previously by others, the gene replacement strategy, involving heart-specific silencing of fly genes and simultaneous expression of normal or mutant human alleles, is exceptionally intriguing. Unfortunately, excitement is severely tempered due to the use of standard P element-mediated germline transformation. First, we must assume the RNAi does not target the products of the human alleles, since no information regarding design is presented. This should be demonstrated. Second, no data related to transgene expression is given. Perhaps the WDR5-K7Q has lower expression levels than WDR5 and, hence, a distinct rescue potential? Finally, what about insertional effects? Were results consistent among multiple transgenic lines? Use of site-specific recombinase technologies and verification of equivalent transgene expression levels are recommended.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"High throughput in vivo functional validation of candidate congenital heart disease genes in *Drosophila*\" for further consideration at *eLife*. Your revised article has been evaluated and discussed by K VijayRaghavan as the Senior editor and a Reviewing editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The editors remain concerned about the responses to points 7 and 8 in your itemised responses to reviewer\'s concerns. Specifically, they note a completely different narrative has been submitted in response to concerns about 1. the nature of the control lines uses for the study; and 2. the uses of P-element versus targeted chromosome integration for generation of transgenic lines. The revisions put forward are completely different from what was originally submitted. At a minimum, these \"errors\" appear to reflect a sloppiness in the preparation of the manuscript that remains of concern to the editors. For this manuscript to be considered further, the authors must provide a reason and concrete evidence that these major technological issues were mistakenly recorded incorrectly.

10.7554/eLife.22617.015

Author response

*Essential revisions:*

*1) Could over-expression of 4xHand-Gal4 sensitize flies to RNAi knockdown phenotypes? How would this be tested?*

This is formally possible but we do not perceive an obvious mechanism for how or why this might occur, as we understand the question, across the fly genome. As a result we did not directly test this possibility. However, the fact that our unbiased screen (using 4xHand-Gal4) of approximately 800 *Drosophila* genes yielded only 6% developmental lethals strongly suggests that 4xHand-Gal4 expression did not sensitize flies to knockdown phenotypes. Text addressing this point has now been added to Results section.

*2) We disagree that gain of function variants will be rare. New insights into this for transcription factors has come to light -- see for example Luna-Zurita et al. Cell 2016 and Bouveret et al. eLife 2015 -- even apparently null proteins can have gain of function effects. There are in fact a number of ways through which interruption of conserved domains in multidomain proteins may have gain of function effects. I think this should be considered more carefully in the Discussion in the context of limitations of the approach.*

We are grateful to the reviewers for raising this point and directing our attention to these insightful articles. In response, we have addressed this point more carefully in the Discussion in the context of limitations of our approach.

*3) One issue that should be addressed is the rationale for the choice of genes for the various analyses. [Figure 3](#fig3){ref-type="fig"} tests the expression levels of six genes when knocked down, but the choice of these genes, and why all 26 were not tested, is not clear. In fact there are certain biases in this study in the sense that one might expect severe defects in any cell type expressing loss or gain of function alleles for chromatin modifying genes, given their global function in epigenetic regulation. We accept that these examples serve to highlight the phenotyping pathway used and the range of defects that can be generated. However, the paper would be strengthened by including some examples of candidates for the Zaidi study where there is mortality or a strong heart phenotype when the gene is knocked down that reveals its totally unknown functions in heart development and cellular function.*

We have now added text to the Results explaining our selection of the six genes tested in the experiments illustrated in [Figure 3](#fig3){ref-type="fig"}. We did not test all 26 genes by quantitative PCR because we tested multiple RNAi lines for all of them, and in each case observed consistent phenotype outcomes. We have also added text to emphasize why we chose to focus more detailed analysis on the phenotypic consequences of knocking down genes involved in chromatin modification pathways. We agree with the reviewer that one might expect to see severe defects from loss of function of chromatin modifying genes in any cell type, but in fact we observed a normal heart phenotype upon silencing of Lid, one of the reasons for examining this gene by qRT-PCR analysis. To address the reviewer's comment that the paper would be strengthened by revealing heretofore unknown functions of candidate genes, we respectfully submit that ours is a functional validation study, rather than a novel gene identification study (as clearly indicated by the title, \"High throughput in vivo functional validation of candidate congenital heart disease genes in *Drosophila*\"). Therefore, we argue that in this sense the reviewer's suggestion is outside the scope of our current submission.

*4) Overall, the description of Methods is seriously lacking in detail. The authors should indicate all of the primer sequences that were used, and all of the RNAi lines should be listed in order that the results can be replicated accurately. The dye angiography method does not include detail about how the data was analyzed.*

We now provide information on all primer sequences ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}) and list all RNAi lines ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). We have added more details and information on how the dye angiography data was analyzed.

*5) We are not convinced that appropriate statistical tests were used when comparing multiple genotypes. Our understanding is that simple t-tests might not be appropriate, but analysis of variance should initially be used. Moreover, simple t-tests can only be used when the sample variances are comparable. An expert statistical review is advised.*

We have now added a "Statistical analysis" section to the Materials and methods, providing much more detail on the statistical tests we used to analyze our data. We have consulted with a statistics expert to review our methods.

*6) It is mentioned that \"Interestingly, the \"top 26\" genes identified by the PCGC study all have conserved Drosophila homologs, but the involvement of these genes in Drosophila heart development had not previously been assessed.\" This is inaccurate. Neely et al. (2010) investigated 18/26 of these genes, many of which when silenced using a similar cardiac-specific approach, reduced lifespan. While all were screened for developmental lethality, only one was categorized as a \"developmentally lethal gene\". The low hit number was potentially due to inadequate RNAi-mediated knockdown relative to that afforded by the 4X-Hand driver described here. Nonetheless, involvement of \~70% of the 26 genes in cardiac development was indeed assessed, and the fact that this highly-related manuscript was not cited and the overlap clarified needs correction.*

We are very grateful to the reviewers for pointing this out. We have added text addressing the overlap, and appropriately cite the related publication.

*7) For all analysis depicted in [Figures 4](#fig4){ref-type="fig"}--[6](#fig6){ref-type="fig"}, information related to the control line(s) or the RNAi stock numbers used, is not provided. This is critical for data interpretation and to rule out genetic background effects, which can contribute to differences in structure/physiology. If the experiments are inappropriately controlled, they must be repeated accordingly. For example, w^1118^ is not an ideal control for the experiments outlined in [Figure 3](#fig3){ref-type="fig"}.*

We have added text to clarify the nature of the control lines and provide a comprehensive inventory of all RNAi lines used ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). We also made changes to the labels in all figures that used control flies, and added to the figure legends to clearly state the genotype of each groups of control flies.

*8) Unlike developmental/survival analysis following cardiac-restricted RNAi expression, structural assessments, and fluorescent dye pumping capacity, which have all been performed previously by others, the gene replacement strategy, involving heart-specific silencing of fly genes and simultaneous expression of normal or mutant human alleles, is exceptionally intriguing. Unfortunately, excitement is severely tempered due to the use of standard P element-mediated germline transformation. First, we must assume the RNAi does not target the products of the human alleles, since no information regarding design is presented. This should be demonstrated. Second, no data related to transgene expression is given. Perhaps the WDR5-K7Q has lower expression levels than WDR5 and, hence, a distinct rescue potential? Finally, what about insertional effects? Were results consistent among multiple transgenic lines? Use of site-specific recombinase technologies and verification of equivalent transgene expression levels are recommended.*

We apologize profusely for mistakenly describing our transgenic lines as having been produced by standard P element-mediated transformation. This was incorrect! In fact, our gene replacement strategy involving heart-specific silencing of fly genes and simultaneous expression of normal or mutant human alleles used a *pUASTattB* vector for fixed chromosomal docking site to effect germline transformation. We have corrected the text of Materials and methods accordingly and hope that in so doing we have restored reviewer excitement. The RNAi target sequence silencing the endogenous *Drosophila* WDS gene is not expected to silence WDR5, since there is over one third of the targeting sequence are mismatch when compared to the human WDR5 sequence. In addition, phenotypic rescue effects from human cDNA expression indicated that even if silencing of human genes did occur at very low level it did not prevent our analysis, since it will have same effects to both the wild type and the mutant allele of human WDR5. Insertional effects is no longer an issue since both the wild type and the mutant allele of human WDR5 were indeed inserted to the same chromosome location and should have the same level of expression.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*Thank you for resubmitting your work entitled \"High throughput* in vivo functional validation of candidate congenital heart disease genes in Drosophila\" for further consideration at eLife. Your revised article has been evaluated and discussed by K VijayRaghavan (Senior editor) and the Reviewing editor.

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:*

*The editors remain concerned about the responses to points 7 and 8 in your itemised responses to reviewer\'s concerns. Specifically, they note a completely different narrative has been submitted in response to concerns about 1. the nature of the control lines uses for the study; and 2. the uses of P-element versus targeted chromosome integration for generation of transgenic lines. The revisions put forward are completely different from what was originally submitted. At a minimum, these \"errors\" appear to reflect a sloppiness in the preparation of the manuscript that remains of concern to the editors. For this manuscript to be considered further, the authors must provide a reason and concrete evidence that these major technological issues were mistakenly recorded incorrectly.*

We are deeply appreciative and grateful for the continued consideration of our manuscript "High throughput in vivo functional validation of candidate congenital heart disease genes in *Drosophila*", and the concern for credible evidence and reasoning to show that in addressing points 7 and 8 of the itemized reviewer concerns we indeed addressed erroneously recorded information and that the text now accurately describes the actual techniques and approaches that were employed. We do sincerely apologize for these oversights that occurred in the initial preparation of our manuscript, and agree that addressing such sloppiness indeed requires extended care and consideration on our part to overcome the completely justified concerns of the editors.

To clarify what occurred with respect to describing the "nature of the control lines uses for the study": *w^1118^* was used throughout the course of our experiments as an abbreviated form of "4xHand-Gal4 crossed to *w^1118^*" which always served as our control. This practice was internally consistent with our use of "GeneX" as an abbreviated form of "4xHand-Gal4 crossed to UAS-GeneX-RNAi" as a descriptor of the experimental test lines that were being analyzed in large numbers during the course of our study. Unfortunately, use of the *w^1118^*abbreviation for the control lines was used in our initial manuscript preparation, and proved misleading. We are grateful for the editor's detection of this oversight, and for this second opportunity to clarify the nature of the control lines and guarantee the accurate reporting and interpretation of our findings.

With respect to concern regarding "the uses of P-element versus targeted chromosome integration for generation of transgenic lines": indeed "targeted chromosome integration" is the superior approach in this case to use of "P-element mediated random integration" and this experiment was in fact carried out using a targeted chromosome integration approach. We apologize that in initially preparing our manuscript we erroneously inserted previously drafted text from a different study's "Materials and methods" section, then failed to make the changes required to correctly describe our approach. Again, we sincerely apologize for this sloppiness.

[^1]: These authors contributed equally to this work.
